脂质过氧化产物HNE在阿尔茨海默病发病机制及进展中的作用。
Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease.
作者信息
Butterfield D Allan, Bader Lange Miranda L, Sultana Rukhsana
机构信息
Department of Chemistry, Center of Membrane Sciences, Sanders-Brown Center on Aging, University of Kentucky, Lexington KY 40506-0055, USA.
出版信息
Biochim Biophys Acta. 2010 Aug;1801(8):924-9. doi: 10.1016/j.bbalip.2010.02.005. Epub 2010 Feb 20.
Abstract
Alzheimer's disease (AD) is an age-related neurodegenerative disorder. A number of hypotheses have been proposed to explain AD pathogenesis. One such hypothesis proposed to explain AD pathogenesis is the oxidative stress hypothesis. Increased levels of oxidative stress markers including the markers of lipid peroxidation such as acrolein, 4-hydroxy-2-trans-nonenal (HNE), malondialdehyde, etc. are found in brains of AD subjects. In this review, we focus principally on research conducted in the area of HNE in the central nervous system (CNS) of AD and mild cognitive impairment (MCI), and further, we discuss likely consequences of lipid peroxidation with respect to AD pathogenesis and progression. Based on the research conducted so far in the area of lipid peroxidation, it is suggested that lipid accessible antioxidant molecules could be a promising therapeutic approach to treat or slow progression of MCI and AD.
摘要
阿尔茨海默病（AD）是一种与年龄相关的神经退行性疾病。人们提出了许多假说来解释AD的发病机制。其中一个用来解释AD发病机制的假说是氧化应激假说。在AD患者的大脑中发现氧化应激标志物水平升高，包括脂质过氧化标志物，如丙烯醛、4-羟基-2-反式壬烯醛（HNE）、丙二醛等。在这篇综述中，我们主要关注在AD和轻度认知障碍（MCI）的中枢神经系统（CNS）中HNE领域所开展的研究，此外，我们还讨论了脂质过氧化对AD发病机制和进展可能产生的影响。基于迄今为止在脂质过氧化领域所开展的研究，有人提出脂质可及的抗氧化分子可能是治疗或延缓MCI和AD进展的一种有前景的治疗方法。
相似文献
1
Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease.
Biochim Biophys Acta. 2010 Aug;1801(8):924-9. doi: 10.1016/j.bbalip.2010.02.005. Epub 2010 Feb 20.
2
Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD.
Brain Res. 2009 Jun 5;1274:66-76. doi: 10.1016/j.brainres.2009.04.009. Epub 2009 Apr 15.
3
Role of by-products of lipid oxidation in Alzheimer's disease brain: a focus on acrolein.
J Alzheimers Dis. 2010;21(3):741-56. doi: 10.3233/JAD-2010-100405.
4
Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain.
Free Radic Biol Med. 2013 Sep;62:157-169. doi: 10.1016/j.freeradbiomed.2012.09.027. Epub 2012 Oct 5.
5
Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease.
Neurobiol Dis. 2008 Apr;30(1):107-20. doi: 10.1016/j.nbd.2007.12.007. Epub 2008 Jan 5.
6
Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment.
Neurosci Lett. 2006 Apr 24;397(3):170-3. doi: 10.1016/j.neulet.2005.12.017. Epub 2006 Jan 4.
7
Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease.
Neurobiol Aging. 2006 Aug;27(8):1094-9. doi: 10.1016/j.neurobiolaging.2005.06.004. Epub 2005 Jul 1.
8
Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease.
Neurochem Int. 2006 Jun;48(8):679-86. doi: 10.1016/j.neuint.2005.12.003. Epub 2006 Feb 17.
9
Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease.
J Cell Mol Med. 2008 Jun;12(3):987-94. doi: 10.1111/j.1582-4934.2008.00163.x.
10
Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products.
Neurochem Res. 2004 Dec;29(12):2215-20. doi: 10.1007/s11064-004-7028-0.
引用本文的文献
1
Ferroptosis in central nervous system injuries: molecular mechanisms, diagnostic approaches, and therapeutic strategies.
Front Cell Neurosci. 2025 Jul 22;19:1593963. doi: 10.3389/fncel.2025.1593963. eCollection 2025.
2
Protective Effects of Statins against Alzheimer Disease.
Ewha Med J. 2023 Oct;46(4):e17. doi: 10.12771/emj.2023.e17. Epub 2023 Oct 31.
3
Baicalin protects neurons from oxidative stress and apoptosis induced by glutamate excitotoxicity in HT-22 cells.
J Vet Sci. 2025 May;26(3):e29. doi: 10.4142/jvs.24334.
4
Lipophilic fluorescent products as a potential biomarker of oxidative stress: A link between central (brain) and peripheral (blood).
J Res Med Sci. 2024 Jul 12;29:38. doi: 10.4103/jrms.jrms_671_23. eCollection 2024.
5
Exploring the Role of Bergamot Polyphenols in Alleviating Morphine-Induced Hyperalgesia and Tolerance through Modulation of Mitochondrial SIRT3.
Nutrients. 2024 Aug 9;16(16):2620. doi: 10.3390/nu16162620.
6
Study of multifunctional anti-AD ligands: design, synthesis, X-ray crystal structure and biological evaluation of diosmetin derivatives.
Mol Divers. 2025 Apr;29(2):1323-1335. doi: 10.1007/s11030-024-10913-w. Epub 2024 Jun 27.
7
A comprehensive bibliometric analysis of global research on the role of acrolein in Alzheimer's disease pathogenesis: involvement of amyloid-beta.
Front Aging Neurosci. 2024 May 9;16:1378260. doi: 10.3389/fnagi.2024.1378260. eCollection 2024.
8
Mitochondria Dysfunction and Neuroinflammation in Neurodegeneration: Who Comes First?
Antioxidants (Basel). 2024 Feb 16;13(2):240. doi: 10.3390/antiox13020240.
9
Ferroptosis mechanism and Alzheimer's disease.
Neural Regen Res. 2024 Aug 1;19(8):1741-1750. doi: 10.4103/1673-5374.389362. Epub 2023 Nov 8.
10
Overexpression of Glutathione S-Transferases in Human Diseases: Drug Targets and Therapeutic Implications.
Antioxidants (Basel). 2023 Nov 6;12(11):1970. doi: 10.3390/antiox12111970.
本文引用的文献
1
Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis.
Proteomics Clin Appl. 2009 Jun 1;3(6):682-693. doi: 10.1002/prca.200800161.
2
In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP.
Free Radic Biol Med. 2010 Jan 1;48(1):136-44. doi: 10.1016/j.freeradbiomed.2009.10.035. Epub 2009 Oct 23.
3
Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment.
J Bioenerg Biomembr. 2009 Oct;41(5):441-6. doi: 10.1007/s10863-009-9241-7.
4
Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer's disease.
Biomed Res. 2009 Aug;30(4):227-33. doi: 10.2220/biomedres.30.227.
5
Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease.
Exp Neurol. 2009 Aug;218(2):286-92. doi: 10.1016/j.expneurol.2009.03.042. Epub 2009 Apr 7.
6
Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal.
Exp Neurol. 2008 Sep;213(1):114-21. doi: 10.1016/j.expneurol.2008.05.014. Epub 2008 May 29.
7
Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease.
J Cell Mol Med. 2008 Jun;12(3):987-94. doi: 10.1111/j.1582-4934.2008.00163.x.
8
Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease.
Neurobiol Dis. 2008 Apr;30(1):107-20. doi: 10.1016/j.nbd.2007.12.007. Epub 2008 Jan 5.
9
Promotion of amyloid beta protein misfolding and fibrillogenesis by a lipid oxidation product.
J Mol Biol. 2008 Apr 4;377(4):1236-50. doi: 10.1016/j.jmb.2008.01.057. Epub 2008 Jan 30.
10
Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases.
CNS Neurol Disord Drug Targets. 2007 Dec;6(6):411-23. doi: 10.2174/187152707783399201.
Zotero 插件